Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sight Sciences ( (SGHT) ) has provided an update.
On March 4, 2026, Sight Sciences reported fourth-quarter 2025 revenue of $20.4 million, up 7% year-on-year, and full-year 2025 revenue of $77.4 million, down 3% versus 2024, as glaucoma sales were flat and dry eye revenue declined for the year. The company maintained high gross margins of 87% in the quarter and 86% for the year, while cutting full-year operating expenses by 13% and narrowing its net loss to $38.4 million, or $0.74 per share.
Fourth-quarter 2025 results showed a return to growth in Interventional Glaucoma and a sharp pickup in Interventional Dry Eye revenue to $0.7 million, helped by higher pricing and recent reimbursement gains. Operating discipline reduced quarterly cash usage to $0.4 million and left the company with $92 million in cash at year-end, and management framed these trends as strengthening Sight Sciences’ platform as it pursues growth in glaucoma and reimbursed dry eye procedures.
Sight Sciences also issued 2026 guidance, projecting revenue of $82 million to $88 million, implying 6% to 14% growth over 2025 driven by modest gains in glaucoma and a rebound in dry eye revenue to $5 million to $7 million. The company plans to modestly increase adjusted operating expenses in 2026 to fund expanded market access and commercial resources, particularly to scale the reimbursed dry eye market and standalone glaucoma opportunities, signaling continued investment-led growth despite ongoing losses.
The most recent analyst rating on (SGHT) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Sight Sciences stock, see the SGHT Stock Forecast page.
Spark’s Take on SGHT Stock
According to Spark, TipRanks’ AI Analyst, SGHT is a Neutral.
The score is held down primarily by weak financial performance (sharp TTM revenue decline, large losses, and ongoing cash burn) and a soft technical setup (below key moving averages with negative MACD). These are partially offset by a more constructive earnings-call outlook (raised revenue guidance and lower opex guidance, plus reimbursement progress for TearCare), while valuation is only modestly supportive due to a loss-driven negative P/E and no stated dividend yield.
To see Spark’s full report on SGHT stock, click here.
More about Sight Sciences
Sight Sciences, Inc. is a Menlo Park-based eyecare technology company that develops and commercializes interventional technologies for glaucoma and dry eye disease. The company focuses on building a leading position in the large and growing interventional glaucoma and interventional dry eye markets through its commercial infrastructure and reimbursement-driven growth strategy.
Its product portfolio is organized into Interventional Glaucoma and Interventional Dry Eye segments, with revenue primarily derived from devices used by ophthalmic specialists. Sight Sciences targets both combined cataract and standalone glaucoma procedures, as well as reimbursed dry eye interventions, aiming to leverage synergies between these segments to scale its presence in interventional eye care.
Average Trading Volume: 285,164
Technical Sentiment Signal: Sell
Current Market Cap: $278.1M
Find detailed analytics on SGHT stock on TipRanks’ Stock Analysis page.